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Summary Serum samples from 82 patients with epithelial ovarian cancer, previously assayed for CA125, were
assayed for circulating colony-stimulating factor 1 (CSF-1). An elevated CSF-1 concentration (>450 U ml-'
or >5.42 ng ml-') was significantly associated with a worse survival (P = 0.02). The predictive value of raised
CSF-1 levels was retained whether the first available sample for all patients (n = 82) or the first sample at the
start of chemotherapy (n = 41) was considered. Mean CSF-1 levels (n = 14) dropped significantly during six
courses of platinum-based chemotherapy (P= 0.02). Although an elevated CA125 concentration appeared to
be a prognostic indicator in the total population (n = 82), it was not related to prognosis in the group of
patients from whom samples had been drawn at the start of chemotherapy. In a Cox proportional hazards
model, CSF-1, but not CA125, was significantly associated with outcome following adjustment for stage, grade
and degree of surgical clearance.
Although progress has been made in establishing meticulous
operative staging of ovarian cancer and defining basic prin-
ciples of therapy, there has not been a dramatic change in
survival rates since the 1960s (Griffiths et al., 1986). This
bleak outlook is primarily due to the indolent early course of
the disease, resulting in an advanced stage at presentation in
70% of all patients. However, even in patients presenting
with early disease, an extensive surgical treatment does not
guarantee cure and new variables correlating with the malig-
nant potential of the cancer cells would be clinically valuable
in the selection of adjuvant therapy for individual patients in
early-stage ovarian cancer. Here we report our findings on
the predictive value of two tumour 'markers', CA125 and
colony-stimulating factor 1 (CSF-1), during the course of
ovarian cancer.
CA125 is the antigen recognised by the monoclonal anti-
body, OC125, produced by immunising Balb/c mice with a
cell line, OVCA 433, cultured from the ascitic fluid of a
patient with a papillary serous cystadenocarcinoma of the
ovary (Bast et al., 1981). Initially it was thought to be specific
for ovarian (Kawabat & Bast, 1983) and gastrointestinal
malignancies (Haga et al., 1986), but subsequently it was
found to be raised in a variety of benign conditions including
pregnancy, pelvic inflammatory disease (Haga et al., 1986;
Halila et al., 1986) and cirrhosis, suggesting it to be a marker
of non-specific peritoneal damage (Redman et al., 1988).
CA125 serum levels have since been shown to have a high
sensitivity and specificity for predicting response to chemo-
therapy in ovarian cancer patients as well as for detecting
relapse. Most importantly, elevated CA125 levels were found
to be correlated with the amount of residual disease in a
multiple regression analysis (Hawkins et al., 1989).
CSF-l was originally distinguished from other colony-
stimulating factors by its ability to promote survival, prolifer-
ation and differentiation of macrophages from bone marrow
progenitor cells (Stanley, 1979; Tushinski et al., 1982). Subse-
quently it was shown to act by binding to and activating a
high-affinity membrane tyrosine kinase receptor, the protein
product of the oncogene c-fms (Guilbert & Stanley, 1980;
1986; Sherr et al., 1985; Yeung et al., 1987). A wide range of
non-oncoplastic and tumour cells have since been document-
ed to synthesise CSF-1. These include endometrium, placen-
tal trophoblast, endothelial cells, fibroblasts, some T cells,
interdigitating reticulum cells and tumours of various origins
as well as tumour-derived cell lines (reviewed by Praloran,
1991). Many tumours and tumour-derived cell lines express
significant levels of the CSF-1 receptor protein as well, and a
possible autocrine role of this growth factor in tumorigenesis
has been suggested (Kacinski et al., 1991). The normal
steady-state circulating CSF-I concentration is regulated by
sinusoidally located macrophages, which remove the growth
factor from the circulation by CSF-1 receptor-mediated
endocytosis and intracellularly destroy it (Bartocci et al.,
1987). In vivo animal studies, using ['25I]CSF-l as tracer,
showed the half-life ofCSF-I in the circulation to be approx-
imately 10 min (Bartocci et al., 1987). During pregnancy the
very high uterine synthesis of CSF-1 may contribute to the
slightly elevated circulating CSF-I concentration (Bartocci et
al., 1986; Pollard et al., 1987). Modest elevations in the
circulating CSF-1 concentration are evident in disease states
such as myeloproliferative disorders (Gilbert et al., 1989;
Janowska-Wieczorek et al., 1991) and in ovarian cancer
patients, in whom they were highly correlated with the
presence of active disease (Kacinski et al., 1989a). We set out
here to evaluate circulating CA125 and CSF-1 levels during
the course of ovarian cancer. We specifically searched for (1)
a correlation between these two markers at different time
points, (2) the predictive value of elevated levels on patient
survival and (3) a change in CSF-1 levels during chemo-
therapy treatment.
Materials and methods
Patients
Eighty-two patients (mean age 52) were treated at Institut
Curie between 1982 and 1988. Patients' tumours were charac-
terised as follows: all 82 tumours were of epithelial origin (70
serous, two mucinous, five endometrioid, two clear cell and
three undifferentiated adenocarcinoma). Staging at diagnosis
was: IA, 8; IB, 5; IC, 4; IIA, 5; IIB, 3; IIC, 2; III, 46; IV, 9.
One stage IA patient was treated prophylactically because of
a strong family history of ovarian, colon and breast cancer;
five stage I (A-C) patients had post-surgical chemotherapy
for ruptured cyst during the procedure; six stage IA, three
stage IB, two stage IC and one stage IIA patients had no
chemotherapy. Chemotherapy was administered in 70 patients
(85%) and was started 4-5 weeks after primary surgery.
Twelve patients were treated for recurrent tumour. Grading
was available in 72 patients: 40 (56%) were well differ-
entiated, 28 (39%) moderately well and four (5%) were
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poorly differentiated. Forty-five patients (55%) had a com-
plete surgical resection of their disease; 37 (45%) were
incomplete. A second-look operation was carried out in 50
patients (60%) who had a complete clinical and radiological
remission following six courses of chemotherapy. Twenty-
nine out of 50 (58%) were surgically free ofdisease, ofwhom
24 (83%) also had a pathological complete remission. The
median follow-up for this patient population was 41 months.
Twenty-two out of 82 (27%) patients were alive without
recurrence at the time of analysis, in nine disease had recur-
red and 51/82 (62%) suffered recurrence and died. The
median time to recurrence was 27 months for the total
population; median survival was 56 months.
The effect of surgery on CSF-I serum levels was tested in
ten patients who had surgery for either malignant (six) or
benign (four) disease. Serum samples were collected prior to
surgery, immediately after surgery, on day 1 following
surgery as well as prior to discharge or at a follow-up visit.
Serum samples
Frozen serum samples which had been previously drawn for
routine CA125 assay from 82 ovarian cancer patients of
Institut Curie were stored at - 30°C until use. Radio-
immunoassay (RIA) was carried out with iodinated recom-
binant CSF-I (a gift from Chiron, Emeryville, CA, USA)
and an anti-CSF-l antiserum as previously described (Janow-
ska-Wieczorek et al., 1991). A total of 420 serum samples
were assessed and results are expressed in ng ml- 1. In a
recent study (Janowska-Wieczorek et al., 1991) 64 healthy
American controls had normally distributed CSF-1 serum
concentrations with a mean concentration of 372 ± 111 U
ml-', equivalent to 4.48 ± 1.3 ngml-'. Serum CA125 concen-
trations were assayed by solid-phase immunoassay (CA125-
EIA, Abbott Park, IL, USA).
For 41 of these patients, samples had been collected at or
immediately after primary surgery. Samples were collected
from the remaining 41 patients during the periods of initial
treatment or observation following treatment, prior to recur-
rence. Survival curves were drawn according to the first
available serum values of CSF-1 and CA125 either for the
total group or for the 41 patients for whom samples were
collected around the time of primary surgery. Sequential
samples at 1, 3 and 6 months ofchemotherapy were available
on 14 patients, and changes of CSF-I during the course of
chemotherapy treatment were documented for these patients.
Fifty patients had a second-look operation. Correlations with
CSF-1 and CA125 levels were sought at three different time
points during the course of the disease: at the start of
chemotherapy, at second look and at recurrence. The predic-
tive value of serum concentrations of CA125 and of CSF-1 at
the time of a second-look operation was tested. The relative
importance of an elevated CSF-1 concentration vs an
elevated CA12S concentration as a prognostic indicator was
tested in a proportional hazards model as described by Cox
(1972).
Statistical methods
BMDP programs were run on a VAX 6000 computer. Sur-
vival curves were drawn using Kaplan-Meier (Kaplan &
Meier, 1958) estimates and comparison of survival distribu-
tions was made by log-rank test (Mantel 1966). Serum
CA125 and CSF-1 levels were available on the 82 patients at
various time points during the course of the disease and
survival estimates according to normal/raised levels were cal-
culated according to the first available sample (n = 82) for
any patient, as well as according to the first sample at the
start of chemotherapy (n = 41). The cut-off level for CA125
measurements (35 U ml-') had been previously defined as the
most discriminant marker of tumour presence (CA125 levels
were below 35 U ml- -in 95% normal controls). In the pre-
sent series 77% of patients had at least one measurement
with a value above 35 U ml'.
In an earlier study of American patients with ovarian
cancer, a cut-off of 500Uml-' (6.02ngml') for CSF-1
measurements had been chosen in an attempt to discriminate
between the presence or absence of disease and to maximally
reduce false-positive (3%) and false-negative (9%) results
(Kacinski et al., 1989b). Previous studies with normal indi-
viduals had indicated that serum CSF-1 concentrations were
normally distributed in the range 1.7-7.1 ngml' (Gilbert et
al., 1989). In the present study, the median value for the 41
patients for whom a serum measurement at the start of
chemotherapy was available was 5.42 ngml-' (450 Uml-'),
and this value was the most discriminant as a predictor for
patient survival (88% of all patients had at least one
measurement of CSF-1 above 5.42 ng ml-' during the course
of their disease).
Comparison between percentages was by chi-square test,
comparison of means by Student's t-test. A non-parametric
test for paired series (Wilcoxon) was used to compare the
values of CSF-1 at the beginning of chemotherapy and 6
months later. The correlation coefficient between CA125 and
CSF-1 was calculated at different time points during the
course of the disease. The prognostic relevance of CSF-1 and
CA125 was adjusted to stage, grade and surgical clearance in
a proportional hazards model as described by Cox (1972).
Results
Serum levels (ng ml-') were measured by RIA and the
median value for the group of patients on whom measure-
ments at the start of the first treatment were available
(n=41) was 5.42ngml-l (450Uml-'). This cut-off value
proved discriminant as a predictor for patient survival ac-
cording to Kaplan-Meier estimates. The CSF-1 concentra-
tion in six normal (non-pregnant) French control sera ranged
between 0 and 2.6 ngml-'. In 88% of all patients studied, at
least one serum measurement was above the cut-off concen-
tration of 5.42 ng ml- ', if all samples taken at any time point
during the course of the disease are considered. Only 77% of
these patients had at least one CA125 measurement that fell
above the 35 Uml-' cut-off.
A correlation between elevated CSF-1 and elevated CA125
levels at either the start of chemotherapy (41 patients), at
second look (31 patients) or at recurrence (28 patients) was
actively sought, but only a vague correlation appeared to
exist between these two 'markers' at the start of chemo-
therapy (r = 0.3).
The variation in CSF-1 levels during the course of chemo-
therapy could be evaluated on 14 patients who had serial
samples at 0, 3 and 6 months. A significant decrease, as
assessed by a (non-parametric) paired Wilcoxon analysis, was
observed after 6 months of treatment (P = 0.02 Table Ta). Of
these 14 patients, 11 had a complete surgical response; 4/11
were free of microscopic disease. Three patients had no
second-look operation, 2/3 had incomplete disease regression
and one patient progressed. The variations in CA125 levels
during the course of chemotherapy in these patients were
Table I (a) Variation in CSF-1 levels during the course of
chemotherapy (ngml-')
Pretreatment
level At 3 months At 6 months
Mean CSF-1 7.89 5.02 2.04
Standard error 2.07 1.06 0.44
Paired Wilcoxon; variation 0-6 months: P = 0.02
(b) Variation in CA125 levels during the course of chemotherapy
(U ml-')
Pretreatment
level At 3 months At 6 months
Mean CA125 607 40 27
Standard error 180 28 24
Paired Wilcoxon; variation 0-6 months: P = 0.0002.344 S.M. SCHOLL et al.
highly significant (P = 0.0002, Table Tb). The effect of
surgery on CSF-1 levels was tested in ten independent
patients with benign (four) or malignant (six) disease. Sam-
ples were collected prior to and at the end of the procedure,
the following day and at discharge or a follow-up visit. No
significant changes in CSF-I serum levels were seen to be
associated with surgery (paired Wilcoxon analysis).
Survival curves for those 41 patients for whom a pre-
chemotherapy sample was available show a significantly
better survival for patients who had 'normal' CSF-1 values
(Figure 1), compared with those whose levels were elevated
(>5.42 ng ml-'; P = 0.02). The median survival times were
71 months (<5.42) and 23 months (>5.42) respectively.
Tests of the predictive value of elevated CA125 levels on the
same samples (before chemotherapy) did not show any differ-
ence (P = 0.38) and the median survival was 52 and 44
months respectively (Figure 2). However, when data from the
first samples of the total population (including patients with
recurrent disease) were examined, patients with elevated
CAI25 levels had a significantly poorer survival (P = 0.007);
median survival times were 48 and 23 months respectively for
patients with normal and with elevated CA125 levels, and
those with elevated CSF-I levels retained the same predicta-
bility. The predictive value for combined markers (in 41
patients) is shown in Figure 3. The median survival for those
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Figure 1 Survival according to CSF-1 at start of chemotherapy.
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patients who were positive for both 'markers' was 19 months.
If either one was positive, the median survival was 52
months; if both were negative, the median survival time was
not reached by 60 months (P = 0.027).
A total of 50 patients had a second-look operation. Results
for both 'markers' at this time point were available on 31
patients; however 34 patients could be assessed according to
their CA125 levels alone. Table II shows that elevated CSF-l
levels significantly predicted outcome in those patients who
had active disease at second look. The median survival for
patients with elevated CSF-l levels was 17 months; while the
median survival (>56 months) was not reached for the group
with normal CSF-I levels. Elevated CA125 values were also
significantly predictive of outcome. However, the data were
biased by the presence of only two patients with raised
CA125 levels who both died early (17 and 20 months).
A multivariate regression analysis comparing the predictive
value of raised CSF-l and CA125 at the start of chemo-
therapy (n = 41) on survival documents a significantly
increased risk for patients with elevated CSF-l values but no
increased risk for patients with elevated CA125 levels (Table
III).
Discussion
The production of CSF-1 has now been reported in a wide
range of tumours of non-hematopoietic origin (Horiguchi et
al., 1988; Ramakrishnan et al., 1989; Tang et al., 1990, 1992;
Kacinski et al., 1990, 1991; S.M. Scholl et al., submitted).
The CSF-1 receptor has also been shown to be expressed in
the same tumour types and tumour-derived cell lines, favour-
ing the involvement of CSF-I in an autocrine mechanism
supporting tumour growth. Previous work by Kacinski et al.
(1990) documents not only the presence of CSF-1 protein
and transcripts in ovarian cancer, but also the presence of
elevated plasma CSF-I levels in patients with active and
recurrent neoplastic disease (Kacinski et al., 1989a).
A number of essential biological functions of monocytes/
macrophages, including migration (Wang et al., 1988), pro-
duction of proteolytic enzymes (Hamilton et al., 1991) and
down-regulation of their MHC class II antigen expression
(Willman et al., 1989) are inducible by CSF-1. The expression
Table II (a) Predictive value ofelevated CSF-I levels (>5.42 ng ml ')
at second look
Patient group n >5.42 <5.42 P°
All 31 8 23 0.07
Pathological remission 17 5 12 0.46
Active disease 14 3 11 0.04
Time (months)
Figure 2 Survival according to CA125 at start of chemotherapy.
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Figure 3 Survival according to CSF-1 and CA125.
(b) Predictive value of elevated CA125 levels (>35 U ml-') at second
look
Patient group n >35 <35 Pa
All 34 2 32 0.0006
Pathological remission 19 19
Active disease 15 2 13 0.009
aLog-rank test comparing survival.
(c) Marker value at second look
Sensitivity Specifieity PPVb At second look
CSF-I 3/14 (21%) 12/17 (71%) 3/8 (38%)
CA125 2/15 (13%) 19/19 (100%) 2/2 (100%)
bPPV, positive predictive value.
Table III Cox regression analysis ofthe risk ofdeath in patients with
elevated CSF-I or CA125 levels at start of chemotherapy
Parameter Relative risk Confidence interval (90%)
Elevated CSF-1 3.23 1.2-8.86
Elevated CA125 1.95 0.69-5.55
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of CSF-1 and its receptor in both monocytes and metastatic
tumour cells could partly explain the biological basis for
phenotypic parallels between the two cell types. Monocytes,
like metastatic tumour cells, can invade stroma, travel to
distant sites and adhere to parenchyma via specific homing
receptors. We have previously shown that CSF-1 protein and
transcripts are present in invasive (Tang et al., 1992), but not
in in situ breast carcinoma cells (Tang et al., 1990). Ovarian
tumour cells are not prone to early distant metastases and
may have preferential receptors to adhere to the serosa ofthe
peritoneal cavity.
The present study compares the prognostic value ofelevat-
ed CSF-l vs elevated CA125 levels in 82 ovarian cancer
patients. CSF-1 was elevated at least once in 88% of the
present series. Its value for monitoring treatment response in
known cancer patients remains to be assessed in a future
prospective trial, but our present results on a small number
of patients with serial measurements point to a potential use
in the evaluation of treatment efficacy. CA125 was elevated
at least once in 77% of the present series, and except for a
vague correlation between both 'markers' in the pretreatment
samples, the variations in CA125 and CSF-I were not relat-
ed. The major clinical correlate ofraised serum CA125 in 169
patients with epithelial ovarian carcinoma was shown to be
the amount of residual disease (Hawkins et al., 1989). CSF-1,
although more frequently elevated in the present series, is not
ovarian tumour specific and has been shown to be elevated in
other disease states such as myeloproliferative disorders or
tumours ofbreast, placenta and endometrium. Moreover, the
regulation of its production as well as its role in tumours
remains elusive.
Ofparticular interest to us are the clinical findings showing
a correlation between raised CSF-I serum values and a worse
prognosis at all stages of ovarian cancer. When the CSF-I
and CA125 results were entered in a multivariate regression
analysis, only elevated CSF-l emerged as an independent
prognostic factor after adjusting for stage, residual tumour
and grade. Stage at diagnosis, the residual tumour mass after
debulking surgery (Sigurdsson et al., 1983) as well as the
histological grade of the tumour (Hernandez et al., 1984)
have so far been the major prognostic indicators in ovarian
cancer. The histological grade, although correlating with out-
come, is subjective in nature and thus poorly suitable for
routine prognostic evaluation (Hernandez et al., 1984). More
recently, multiploid/aneuploid tumours and a high S-phase
fraction have been shown to be highly correlated with an
increased risk of death from ovarian cancer (Kallionemi et
al., 1988). It is not clear how raised CSF-I levels influence
prognosis. As the detrimental effects of CSF-I could be via a
stimulation of tumour cell growth, it might be of interest to
compare CSF-I levels with S-phase fractions in the same
tumour. In the present study, most patients had well- or
moderately well-differentiated tumours and no correlation
between grade and survival was seen (P = 0.8). Ploidy as well
as S-phase were not available. These variables could there-
fore not be tested independently by us. A prospective trial
comparing CSF-I levels with other known prognostic indi-
cators at the start of treatment together with a detailed
documentation ofCSF-I variations at different time points in
the course of the disease will be helpful in ascertaining its
role as a marker of disease progression or treatment re-
sponse.
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